How many sirna therapeutics drugs are tracked?

Drug Landscape tracks 0 sirna therapeutics (0 marketed, 0 Phase 3, 0 Phase 2, 0 Phase 1).

How fresh is this page?

Refreshed every 30 minutes from primary sources (Drugs@FDA, EMA EPAR, ClinicalTrials.gov, sponsor 8-K filings).

siRNA Therapeutics — Pipeline, Approvals, Sponsors

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Small interfering RNA therapeutics — most clinically deployed via GalNAc conjugation for hepatocyte targeting. Onpattro / Givlaari / Leqvio / Amvuttra. Strong cardiometabolic + rare disease pipeline.

Marketed

Filed

Phase 3

Phase 2

Phase 1

Total

Marketed leaders

No marketed leaders tracked.

Recent approvals (last 30 days)

No approvals in the last 30 days.

Upcoming PDUFA (next 180 days)

No upcoming PDUFA in next 180 days.

Top sponsors in this modality

No sponsor data.

Drug classes within siRNA Therapeutics

No class breakdown.

Subscribe to ongoing alerts

Push every new sirna therapeutics event into your RSS reader:

siRNA Therapeutics firehose — RSS
Recent siRNA Therapeutics approvals only
Upcoming siRNA Therapeutics PDUFA only

Other modalities

Biologics Monoclonal Antibodies Small Molecules Antibody-Drug Conjugates Cell Therapies Gene Therapies Gene Editing mRNA Therapeutics Antisense Oligonucleotides Bispecific Antibodies Vaccines

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing